Imiquimod cream in the treatment of actinic keratoses - 11/05/12
Abstract |
We studied the usefulness of imiquimod cream in the treatment of 3 patients with actinic keratoses. One patient was treated 3 times per week for 4 weeks and had a marked inflammatory response with nearly complete resolution of actinic keratoses. Two subsequent patients were treated in a bilateral paired comparison study. Both patients had similar numbers of actinic keratoses on symmetric areas and treated only one side with imiquimod cream 2 to 3 times per week with frequent rest periods to avoid inflammation. Both experienced marked reductions in actinic keratoses. After 8 weeks, both patients applied imiquimod cream twice per week for 9 months with continued reduction in actinic keratoses on both sides. Treatments were well tolerated. Imiquimod cream appears to be effective in the treatment of actinic keratoses. The main adverse effect is local inflammation, which can be avoided by reducing the frequency of application. (J Am Acad Dermatol 2002;47:S236-9.)
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: 3M Corporation. |
|
This article is part of a supplement sponsored by 3M Pharmaceuticals. |
|
Disclosures: Dr Persaud and Dr Lebwohl have been funded investigators for the 3M Corporation. Dr Lebwohl has been funded by the 3M Corporation for speaking engagements. |
|
Reprint requests: Andrea Persaud, MD, Clinical Dermatology, The Mount Sinai School of Medicine, 5 E 98th St, Box 1048, New York, NY 10029. |
Vol 47 - N° 4S
P. S236-S239 - octobre 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?